Rhonda Farnum Sells 24,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 24,000 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president now owns 336,918 shares of the company's stock, valued at $3,706,098. The trade was a 6.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rhonda Farnum also recently made the following trade(s):

• On Monday, April 21st, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Stock Up 4.5%

Shares of TBPH traded up $0.48 during trading hours on Friday, hitting $11.25. The company had a trading volume of 295,003 shares, compared to its average volume of 276,302. The firm has a market cap of $562.51 million, a price-to-earnings ratio of -11.14 and a beta of -0.09. The business has a fifty day moving average of $9.35 and a 200-day moving average of $9.39. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. On average, equities analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of TBPH. Aquatic Capital Management LLC bought a new position in Theravance Biopharma during the fourth quarter worth about $25,000. GAMMA Investing LLC increased its position in Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 3,281 shares during the period. KLP Kapitalforvaltning AS bought a new position in Theravance Biopharma during the fourth quarter worth about $69,000. AQR Capital Management LLC bought a new position in Theravance Biopharma during the first quarter worth about $101,000. Finally, Teacher Retirement System of Texas bought a new position in Theravance Biopharma during the fourth quarter worth about $103,000. 99.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on TBPH. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $11.33.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.